Key Insights

Highlights

Treatment Research

2 treatments under study, led by Ebvtcrt Cells

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1 (1)

Trial Status

Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT07693881Not ApplicableRecruitingPrimary

Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT06119256Phase 1RecruitingPrimary

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

Showing all 2 trials

Research Network

Common Treatments

  • Ebvtcrt Cells1
  • Rituximab R1

Active Sponsors

  • Nanfang Hospital, Southern Medical University1
  • Chinese PLA General Hospital1

Top Investigators

Activity Timeline